Cargando…

Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect

INTRODUCTION: Osteoporosis is a disease characterized by low bone mineral density and poor bone quality resulting in reduced bone strength and increased risk of fracture. Oral bisphosphonates, first-line therapy for most patients with osteoporosis, are associated with suboptimal adherence to therapy...

Descripción completa

Detalles Bibliográficos
Autor principal: Lewiecki, E Michael
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2899787/
https://www.ncbi.nlm.nih.gov/pubmed/20694061
_version_ 1782183561137225728
author Lewiecki, E Michael
author_facet Lewiecki, E Michael
author_sort Lewiecki, E Michael
collection PubMed
description INTRODUCTION: Osteoporosis is a disease characterized by low bone mineral density and poor bone quality resulting in reduced bone strength and increased risk of fracture. Oral bisphosphonates, first-line therapy for most patients with osteoporosis, are associated with suboptimal adherence to therapy due to factors that include a complex dosing regimen and gastrointestinal intolerance in some patients. Intravenous bisphosphonates address these limitations through infrequent injectable dosing that assures 100% bioavailability. Intravenous zoledronic acid is the newest bisphosphonate to be approved for the treatment of osteoporosis. AIMS: This review assesses the evidence for the therapeutic effects of intravenous zoledronic acid for the treatment of osteoporosis. EVIDENCE REVIEW: Zoledronic acid 5 mg administered as an annual 15-min intravenous infusion has been shown to reduce the risk of vertebral fractures, hip fractures, and other fractures in a three-year randomized, double-blind, placebo-controlled trial in women with postmenopausal osteoporosis. In a randomized, double-blind, placebo-controlled trial in women and men with a recent surgical repair of low-trauma hip fracture, it reduced the risk of new clinical fractures and improved survival. In both studies, zoledronic acid was associated with a good safety profile and was generally well tolerated. Zoledronic acid has the potential to improve clinical outcomes by reducing the risk of fracture in patients with osteoporosis. CLINICAL VALUE: Intravenous zoledronic acid 5 mg every 12 months reduces fracture risk in women with postmenopausal osteoporosis and in women and men with recent low-trauma hip fracture.
format Text
id pubmed-2899787
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-28997872010-08-05 Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect Lewiecki, E Michael Core Evid Review INTRODUCTION: Osteoporosis is a disease characterized by low bone mineral density and poor bone quality resulting in reduced bone strength and increased risk of fracture. Oral bisphosphonates, first-line therapy for most patients with osteoporosis, are associated with suboptimal adherence to therapy due to factors that include a complex dosing regimen and gastrointestinal intolerance in some patients. Intravenous bisphosphonates address these limitations through infrequent injectable dosing that assures 100% bioavailability. Intravenous zoledronic acid is the newest bisphosphonate to be approved for the treatment of osteoporosis. AIMS: This review assesses the evidence for the therapeutic effects of intravenous zoledronic acid for the treatment of osteoporosis. EVIDENCE REVIEW: Zoledronic acid 5 mg administered as an annual 15-min intravenous infusion has been shown to reduce the risk of vertebral fractures, hip fractures, and other fractures in a three-year randomized, double-blind, placebo-controlled trial in women with postmenopausal osteoporosis. In a randomized, double-blind, placebo-controlled trial in women and men with a recent surgical repair of low-trauma hip fracture, it reduced the risk of new clinical fractures and improved survival. In both studies, zoledronic acid was associated with a good safety profile and was generally well tolerated. Zoledronic acid has the potential to improve clinical outcomes by reducing the risk of fracture in patients with osteoporosis. CLINICAL VALUE: Intravenous zoledronic acid 5 mg every 12 months reduces fracture risk in women with postmenopausal osteoporosis and in women and men with recent low-trauma hip fracture. Dove Medical Press 2010-06-15 2009 /pmc/articles/PMC2899787/ /pubmed/20694061 Text en © 2009 Lewiecki, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Lewiecki, E Michael
Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect
title Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect
title_full Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect
title_fullStr Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect
title_full_unstemmed Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect
title_short Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect
title_sort intravenous zoledronic acid for the treatment of osteoporosis: the evidence of its therapeutic effect
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2899787/
https://www.ncbi.nlm.nih.gov/pubmed/20694061
work_keys_str_mv AT lewieckiemichael intravenouszoledronicacidforthetreatmentofosteoporosistheevidenceofitstherapeuticeffect